Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: denosumab, Amgen.

Bo Abrahamsen1, Andy Y T Teng

  • 1Copenhagen University, RASK Osteoporosis Clinic, Department of Medicine, Roskilde County Hospital Koge, Denmark. b.abrahamsen@dadlnet.dk

Current Opinion in Molecular Therapeutics
|December 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence Approaches for Osteoporotic Fracture Risk Prediction Using Administrative Health Data: A Systematic Review.

Calcified tissue international·2026
Same author

The Danish Nationwide osteoporosis cohort trials environment (NOCTE) - a DXA dataset for the 1900-1960 birth cohort.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry·2025
Same author

Introducing FREM<sub>ML</sub>: a decision-support approach for automated identification of individuals at high imminent fracture risk.

Archives of osteoporosis·2025
Same author

An enhanced Fracture Risk Evaluation Model (FREM) using national health data on morbidity and medications.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025
Same author

[Surgical treatment of hyperparathyroidism].

Ugeskrift for laeger·2025
Same author

Early life determinants of skeletal maturation, body composition and endocrine health in young adults (EPIPEAK): protocol for a nationwide birth cohort study.

BMJ open·2025

Denosumab, a fully human monoclonal antibody, targets the RANKL pathway to treat bone loss diseases like osteoporosis. It is currently in phase III clinical trials.

Area of Science:

  • Biotechnology and immunology
  • Bone biology and disease

Background:

  • The RANK/RANKL/osteoprotegerin pathway is crucial in regulating bone metabolism.
  • Dysregulation of this pathway contributes to bone loss conditions.

Purpose of the Study:

  • To develop denosumab, a novel therapeutic agent targeting the RANKL pathway.
  • To evaluate the efficacy of denosumab in treating diseases characterized by bone loss.

Main Methods:

  • Development of a fully human monoclonal antibody (denosumab).
  • Subcutaneous delivery of the therapeutic agent.
  • Targeting the receptor activator of nuclear factor-kappaB ligand (RANKL).

Main Results:

  • Denosumab demonstrates potential for treating bone loss diseases.

Related Experiment Videos

  • Ongoing phase III clinical trials are evaluating its efficacy and safety.

    • Conclusions:

    • Denosumab represents a promising therapeutic strategy for conditions involving bone loss.
    • Further clinical evaluation is necessary to confirm its therapeutic benefits.